USD
( +0.00%
At Close (As of Jan 1, 1970)
$1.53B
Market Cap
29.67
P/E Ratio
1.63
EPS
$49.16
52 Week High
$23.23
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $377M |
| Total Revenue | $631M |
| Cost Of Revenue | $254M |
| Costof Goods And Services Sold | $254M |
| Operating Income | $170M |
| Selling General And Administrative | $172M |
| Research And Development | $0 |
| Operating Expenses | $207M |
| Investment Income Net | - |
| Net Interest Income | -$60M |
| Interest Income | $14M |
| Interest Expense | $74M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $169M |
| Income Before Tax | $99M |
| Income Tax Expense | $29M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $69M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $173M |
| Ebitda | $342M |
| Net Income | $69M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $377M |
| Total Revenue | $631M |
| Cost Of Revenue | $254M |
| Costof Goods And Services Sold | $254M |
| Operating Income | $170M |
| Selling General And Administrative | $172M |
| Research And Development | $0 |
| Operating Expenses | $207M |
| Investment Income Net | - |
| Net Interest Income | -$60M |
| Interest Income | $14M |
| Interest Expense | $74M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $169M |
| Income Before Tax | $99M |
| Income Tax Expense | $29M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $69M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $173M |
| Ebitda | $342M |
| Net Income | $69M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Collegium Pharmaceutical, Inc. is a specialized pharmaceutical company headquartered in Stoughton, Massachusetts, focused on developing and commercializing innovative solutions for pain management. The company offers a diverse portfolio of proprietary drug formulations tailored to address a range of pain-related conditions, reflecting its commitment to improving patient outcomes. With a strategic emphasis on enhancing the quality of care within the pain management landscape, Collegium is well-positioned for continued growth and leadership in the specialty pharmaceutical sector, attracting interest from institutional investors seeking to capitalize on advancements in this critical area of healthcare.